Minot Light Capital Partners, an investment management company, released its Q2 2026 investment letter. A copy of the letter can be downloaded here. In the quarter, the partnership generated gross and net returns of 26.2% and 20.3%, respectively, bringing year-to-date returns to 22.8% gross and 17.1% net. Since inception 21 months ago, gross and net returns reached 56.4% and 40.9%, respectively. The fund attributed the quarter’s performance to strength across several large positions while maintaining a diversified portfolio, limited leverage, and a focus on profitable small and micro-cap companies with strong balance sheets. Minot Light also highlighted improving downside protection and upside participation as momentum-driven market trends began to weaken. In addition, the fund discussed opportunities created by sharp post-IPO declines in high-quality non-technology companies and reiterated its cautious stance toward expensive AI-related and speculative stocks, while remaining open to emerging technology opportunities when valuations and long-term risk-reward characteristics become more attractive. In addition, please check the fund’s top five holdings to know its best picks in 2026.
In its second-quarter 2026 investor letter, Minot Light Capital Partners highlighted Rockwell Medical, Inc. (NASDAQ:RMTI). Rockwell Medical, Inc. (NASDAQ:RMTI) is a healthcare company engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers. On September 21, 2026, Rockwell Medical, Inc. (NASDAQ:RMTI) closed at $8.70 per share. One-month return of Rockwell Medical, Inc. (NASDAQ:RMTI) was 2.09% and its shares lost 38.44% over the past 52 weeks. Rockwell Medical, Inc. (NASDAQ:RMTI) has a market capitalization of $32.51 million with a 52-week trading range between $4.89 and $13.30.
Minot Light Capital Partners stated the following regarding Rockwell Medical, Inc. (NASDAQ:RMTI) in its Q2 2026 investor letter:
“Rockwell Medical, Inc. (NASDAQ:RMTI) is another example of a type of stock that has generated good returns for Minot Light over the past 18 months. It encompasses three characteristics that provide us with a unique opportunity in areas where most institutional small-cap managers cannot or will not participate. These three characteristics are: 1. A sub-$50M market cap / sub-$25M enterprise value (market cap minus net cash on the balance sheet), 2. A stock that falls below $1.00/share, and 3. A company that announces a reverse stock split to make sure the stock goes back up above $1.00/share to ensure it is not de-listed.
When some combination of these three things comes together, we are often able to purchase a relatively healthy company with a reasonable growth outlook at or below its net cash value on the balance sheet. In previous letters we have spoken about both Outset Medical (OM) and MaxCyte (MXCT), both of which were companies where we were able to purchase shares below net cash on the balance sheet, despite core businesses with several attractive characteristics. We will admit, these can be some of the most frustrating stocks to own in the near-term, but over time, as we have been able to lower our average cost on both names, they have made us money and eventually contributed nicely to partnership returns. In our view, Rockwell is at least as attractive as OM and MXCT were at their lows, and potentially more so, simply because it should now be sustainably cash flow positive going forward, whereas OM and MXCT are still burning cash.” (Click here to read the full text)
Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: finance.yahoo.com
